| lung cancer (metastatic) | All results are NS for efficacy inferior to pemetrexed in terms of ORR in Smit, 2009 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Smit, 2009 | vs pemetrexed | PFS 0.67 [0.51; 0.89] | ORR 2.91 [1.18; 7.15] | OS 0.85 [0.62; 1.17] | | Chen, 2008 | vs pemetrexed | | | | | Hanna, 2004 | vs pemetrexed | | | | | Jose, 2011 | vs pemetrexed | | | | | Li, 2012 | vs pemetrexed | | | | | Socinski, 2010 | vs pemetrexed | | | | | Sun, 2013 | vs pemetrexed | | | |
| Trial | Treatments | Patients | Method |
|---|
| Smit, 2009 | Pemetrexed plus carboplatin (n=-9) vs. pemetrexed (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: phase 2 | | Chen, 2008 | (n=34) vs. (n=33) | | Sample size: 34/33 Primary endpoint: FU duration: | | Hanna, 2004 | pemetrexed 500 mg/m(2) intravenously (i.v.) day 1 with vitamin B(12), folic acid, and dexamethasone (n=283) vs. docetaxel 75 mg/m(2) i.v. day 1 with dexamethasone every 21 days (n=288) | patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy | Sample size: 283/288 Primary endpoint: overall survival FU duration: | | Jose, 2011 | carboplatin (area under the curve = 5 mg/ml × min) and pemetrexed (500 mg/m(2)) 21-day cycle (maximum of six cycles). (n=106) vs. docetaxel (75 mg/m(2)). (n=105) | first-line treatment for advanced, nonsquamous non-small cell lung cancer | Sample size: 106/105 Primary endpoint: survival without treatment-emergent grade 3/4 toxicity FU duration: | | Li, 2012 | pemetrexed 500 mg/m(2) intravenously day 1 with vitamin B12, folic acid, and dexamethasone (n=132) vs. docetaxel 75 mg/m(2) intravenously day 1 with dexamethasone (n=128) | patients with histological or cytological diagnosis of stage IIIB or IV NSCLC, who were not suitable for curative therapy and had failed from prior first line chemotherapy regimen for at least 4 weeks | Sample size: 132/128 Primary endpoint: overall response rate (ORR) FU duration: | | Socinski, 2010 | pemetrexed 500 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to 6 cycles (n=74) vs. docetaxel 75 mg/m and carboplatin area under the curve 6 once every 3 weeks for up to six cycles (n=72) | Patients with stage IIIB (with pleural effusion) or IV non-small cell lung cancer and performance status 0 or 1 | Sample size: 74/72 Primary endpoint: time to disease progression (TTP). FU duration: | | Sun, 2013 | pemetrexed (500 mg/m(2); on Day 1 of each 21-day cycle (n=107) vs. docetaxel (75 mg/m(2) on Day 1 of each 21-day cycle (n=104) | second-line therapy for Chinese patients with locally advanced or metastatic non-small cell lung cancer | open-label Sample size: 107/104 Primary endpoint: FU duration: |
|
